Cancer Therapeutics Training (CT2) Talk | Brett Ewald, PhD
bis
Comer Commons, Moores Cancer Center, Kalifornien
One Molecule, Two Missions: The Development of Radiopharmaceuticals for Cancer Brett Ewald, PhD, is a founding member of Radionetics and serves as Chief Operating Officer. He has 20 years of oncology experience and has led corporate strategy, business development, portfolio management, and clinical development across various organizations. Previously, he served as Senior Vice President at DNAtrix, where Dr. Ewald was instrumental in raising capital, establishing oncology collaborations with Merck, and setting corporate and pipeline strategies. He additionally has held leadership positions at Novartis Pharmaceuticals, helping manage more than 20 oncology clinical programs and working directly on early-stage clinical programs for now-approved oncology drugs BRAFTOVI (encorafenib) and PIQRAY (alpelisib). Dr. Ewald holds a Ph.D. in Pharmacology from The University of Texas MD Anderson Cancer Center, as well as B.A. and B.S. degrees in Economics and Biology from Villanova University.